Navigation Links
Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis

MARIETTA, Ga., Oct. 9 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI). EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food and, if untreated, can lead to poor growth, poor weight gain and failure to thrive in children with CF.

According to the study results, patients with CF and confirmed EPI had an improved coefficient of fat absorption (CFA) during treatment with CREON® compared to treatment with placebo. CFA is calculated based on measures of fat ingestion and fat excretion; assessing the CFA of a patient is a way to measure the absorption of fat as a percentage of fat intake in patients being tested for EPI. The trial reached statistical significance on its primary endpoint, which was CFA.

"These study results demonstrate that CREON® is effective in decreasing the maldigestion and malabsorption associated with pancreatic insufficiency in patients with cystic fibrosis," said Bruce C. Trapnell, MD, Professor of Medicine and Pediatrics at the University of Cincinnati and Cincinnati Children's Hospital Medical Center. "Patients enrolled in this study had poor fat absorption without treatment, which is commonly associated with uncomfortable gastrointestinal symptoms and severe malnutrition. In addition to the impressive increase in fat absorption demonstrated in these individuals, the secondary outcomes of the study have important implications for those involved in the care of these patients."

CREON® was approved by the Food and Drug Administration (FDA) with an indication to treat EPI due to CF or other conditions based on the results of this clinical study. As the first FDA-approved PERT, CREON® was also the first product in the class to provide a Medication Guide with important dosing information, including instructions for administration to infants and toddlers, which is consistent with the CF Foundation Consensus Conference Guidelines.

Study Details

The double-blind, randomized, placebo-controlled two-arm, crossover study examined the efficacy and safety of CREON® (Pancrelipase) Delayed-Release 24,000 lipase unit capsules in subjects aged 12 years or older with EPI due to CF. EPI was confirmed in all subjects by a CFA of <70% without pancreatic enzyme supplementation or fecal elastase <50 micrograms/gram stool within 12 months prior to start of study. Upon analysis of the primary efficacy results, the mean CFA was greater during treatment with CREON® (88.6%) compared with placebo (49.6%), and the difference was statistically significant (p < 0.001). Thus, the study met its primary objective and showed superior efficacy of CREON® over placebo based on CFA. Adverse clinical symptoms including stool frequency, abdominal pain, stool consistency and flatulence, occurred less frequently during treatment with CREON®, compared to treatment with placebo. Additionally, abdominal pain and flatulence were less severe and stool consistency was less watery during treatment with CREON®.

About Exocrine Pancreatic Insufficiency and Pancreatic Enzyme Replacement Therapy

Exocrine pancreatic insufficiency (EPI) is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food. The safety and efficacy of prior formulations of pancrelipase in pediatric patients with EPI due to CF have been described in the medical literature. Prior formulations of pancrelipase have also demonstrated clinical efficacy in those patients through years of clinical experience. PERTs work in patients with EPI by delivering pancreatic enzymes to the small intestine to help break down fats, proteins and carbohydrates in food, thereby acting as a replacement for digestive enzymes physiologically secreted by the pancreas. EPI can occur as a complication of a variety of diseases or conditions, including CF, pancreatic cancer, gastrointestinal surgery and chronic pancreatitis. Statistics show that more than 80% of CF patients have EPI, which usually develops during the first year of life.

The original products in the pancreatic enzyme drug class pre-date modern FDA regulatory requirements. Over the past two decades, products in this class have been allowed to be marketed as prescription drugs without formal NDA approval. In 2004, the FDA required manufacturers to submit New Drug Applications (NDAs) for all pancreatic enzyme replacement therapies in order to remain on the market. By April 2010, all pancreatic enzyme replacement therapies are required to have approved NDAs and must be manufactured under the new guidelines.

Important Safety Information about FDA-Approved CREON®

Warnings and precautions include fibrosing colonopathy, a rare, serious adverse reaction that has been described in association with high-dose use of pancreatic enzyme replacement therapy in the treatment of cystic fibrosis patients. Caution should be exercised when doses of CREON® exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). Care should be taken to ensure that CREON® is not chewed or retained in the mouth to avoid irritation of oral mucosa. Caution should be exercised when prescribing CREON® to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products, including CREON®. Caution should be exercised when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

In the clinical study used to demonstrate the efficacy and safety of FDA-approved CREON®, the incidence of adverse events (regardless of causality) was higher during placebo treatment (71%) than during CREON® treatment (50%). Treatment-emergent adverse events occurring in at least two patients (greater than or equal to 6%) receiving CREON® or placebo were abdominal pain, abdominal pain upper, abnormal feces, cough, dizziness, flatulence, headache, and weight decreased.

CREON® has been approved with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the drug outweigh its risks. As part of the REMS, a Medication Guide with important dosing and safety information applicable to this class of products, including CREON®, is provided for patients and caregivers, with an emphasis on understanding the risk of fibrosing colonopathy as well as the importance of not over- or under-dosing. The FDA requires that the Medication Guide be handed out with every prescription for the drug dispensed.

For full safety and Prescribing Information about the FDA-approved formulation of CREON®, visit

Solvay Pharmaceuticals, Inc., of Marietta, Georgia, is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion and it employs more than 9,000 people worldwide. For more information, visit

Solvay is an international Chemicals and Pharmaceuticals Group with headquarters in Brussels. It employs some 28,300 people in 50 countries. In 2008, its sales amounted to EUR 9.5 billion generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE-Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on NYSE-Euronext at Brussels. Details are available at

    Jessica Riley                           Aaron Estrada
    Solvay Pharmaceuticals, Inc.            Ruder Finn
    (770) 578-5637                          (212) 715-1568      

SOURCE Solvay Pharmaceuticals, Inc.

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
4. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
5. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
6. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
7. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
8. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
9. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2009 Results
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
11. Immucor Announces Fiscal First Quarter Results
Post Your Comments:
(Date:6/23/2020)... ... June 23, 2020 , ... ... a leading provider of center-based, Applied Behavioral Analysis ("ABA") therapy, today announced ... provider in the greater-Indianapolis market. This acquisition will make Lighthouse Autism Center ...
(Date:6/23/2020)... EAST SETAUKET, N.Y. (PRWEB) , ... June 23, ... ... Kaeo, Thailand was completed on May 11, 2020 which now features a greatly ... waterproof the hospital’s new concrete below-grade basement structures, water tanks, and rooftop garden. ...
(Date:6/19/2020)... ... , ... Food Equality Initiative (FEI), a nonprofit with the mission ... disease announced the first of the “ For the Health” webinar series, A Conversation ... 19, 2020, from 11:00, am EST - 12:00 pm EST. , Intentionally planned ...
Breaking Medicine Technology:
(Date:6/28/2020)... Va. (PRWEB) , ... June 26, 2020 , ... ... a call for participation in the revision and redesignation of the ANSI/APSP/ICC-7 2013 ... Hot Tubs, and Catch Basins. PHTA is seeking member participation on the PHTA-7 ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... Inland Empire’s premier residential addiction treatment center, proudly announces that it has reopened ... special preparation for recovery in a world affected by Covid-19. , When social-distancing ...
(Date:6/28/2020)... ... 27, 2020 , ... The FSHD Society announced the opening ... the organization’s history. The online conference takes the place of FSHD Connect, the ... year due to COVID-19. Nearly 300 individuals and families living with FSHD are ...
(Date:6/25/2020)... (PRWEB) , ... June 25, 2020 , ... Denials Management, ... providers on the key steps when filing appeals for denials of mental health and ... to help educate individuals about their appeal rights and explain the steps in the ...
(Date:6/24/2020)... ... June 24, 2020 , ... Dr. Katinka van der ... the most requested guest on the True Grit and Grace podcast. She explains her ... and knowing remission is possible. , After being diagnosed with CRPS about 10 ...
Breaking Medicine News(10 mins):